1. ExecutiveSummary Company: BMDSysOpticalGmbH Copy: No.1/3 Date: February 23rd,2014 Businessplan: 04/2013 12/2016(1. 3.business year) Founder (team): VolkerSchall(CEO) Dr.rer.nat.GertrudLembke(CTO) Anyinformationinthissummaryisconfidential!Reproductionandcopyingrequires theagreementofDeMicco&FriendsGroup! 1 www.demicco.ch

2. DISCLAIMER The contents of this document are strictly confidential and were obtained inter alia from publicly available information. This document (the Concept, Structure & Investors Presentation) is a marketing document and not a regulatory document. The sole purpose of this document is to assist the recipient in deciding whether to proceed with a further investigation of an investment in BMDSys Optical GmbH, registered in Germany, (the COMPANY) and the "Proposed Transaction". This document does not purport to be all inclusive or to contain all the information that a prospective interested party may desire to evaluate the Proposed Transaction. This document has been prepared only for informational purposes relating to the Proposed Transaction only. Neither COMPANY nor its affiliates or representatives assumes any responsibility for the independent verification of any of the information set forth in this document, or of any additional evaluation material made available in connection with any further investigation of the Proposed Transaction. Neither COMPANY nor its affiliates or representatives make any express or implied representation or warranty as to the accuracy or completeness of the information contained in, or for any omissions from, this document or any additional evaluation material made available in connection with any further investigation of the Proposed Transaction. In addition, COMPANY (on its own behalf and on behalf of its affiliates or representatives) expressly disclaims any and all liability which may be based on such information, errors therein or omissions there from. Neither the receipt of this document by any person nor any information contained herein or supplied herewith or subsequently communicated to any person in connection with the Proposed Transaction is or is to be taken as constituting the giving of investment advice to any such person. It is the responsibility of the recipient, before entering into any transaction, to make its own appraisal of the Proposed Transaction, its advantages and risks, without relying exclusively on the information that was provided to the recipient. If it deems necessary or useful, the recipient may consult its own legal, tax, financial, accounting and other professional advisors. 2 In furnishing this document, neither COMPANY nor its affiliates or representatives undertakes any obligation to provide the recipient with access to any additional evaluation material. COMPANY reserves the right to negotiate with one or more parties at any time and to enter into a definitive agreement, without prior notice to the recipient or any other party. COMPANY reserves the right to terminate, at any time, solicitation of indications of interest in the Proposed Transaction or in the further participation in the investigation and proposal process by any party. Finally, COMPANY reserves the right to modify, at any time, any procedures relating to this process without assigning any reason therefore. The information contained herein or made available in connection with any further investigation of the Proposed Transaction is strictly confidential. This document may not be photocopied, reproduced or distributed to any third party at any time without the prior written consent of COMPANY. All communications, inquiries and requests for information relating to these materials should be addressed to COMPANY. COMPANY is the primary contact for the Proposed Transaction. Please direct all inquiries regarding the Proposed Transaction to the representatives of COMPANY referred to below. Interested parties will be required to sign a Non Disclosure Agreement (NDA) and send it, by email and by post/hand, to the address below. De Micco & Friends Group Corporation (advisors,lawyers,auditors) Switzerland and BMDSys OpticalGmbH Germany www.demicco.ch

3. Contents Overview 1. Executivesummary 2. Product 5. Chances and risks 6. Financialplanning 7. Offer for investors 3. Founder and management team 4. Market 3 www.demicco.ch

4. Overview 4 www.demicco.ch

5. Overview Projectdata Entrepreneurs: Planning: Continuation,development and marketing of analready developed technology Businesslocation: RudolfDieselStrae7,89312Gnzburg,Germany Legalform: GmbH(GermanLimited) Companyname: BMDSys OpticalGmbH Startof operation : previous company BMDSys Production GmbH2005 Funding: Own funding and privateequity Futureprospects: 5 VolkerSchalland Dr.rer.nat.GertrudLembke Aunique product for risk stratification of sudden cardiac death (SCD) has been developed that now has to be introduced worldwide. www.demicco.ch

6. 1. ExecutiveSummary 6 www.demicco.ch

7. 1.ExecutiveSummary Product/Businessmodel In the industrialized countries heart diseases are cause of death number one! Worldwide approx. 9 mio. people die per year because of sudden cardiac death (SCD). In Germany there are 100,000 cases per year. In approximately 80 % of all cases high frequent heart arrhythmias are responsible. In principle every person can be in danger. Sudden cardiac death (SCD) is in approx. 50 % of all cases the first manifestation of a heart disease. The affected persons did not know about their heart problem and thus could not take any preventive action. The BMDSys Optical GmbH offers with a unique technical innovation a solution for this problem! 7 www.demicco.ch

8. 1.ExecutiveSummary Product/Businessmodel The diagnostic system developed by BMDSys Optical GmbH allows a cardiologist to estimate the risk for sudden cardiac death within five minutes based on the hearts magnetic signals. The team of BMDSys Optical GmbH and the physicians accompanying the clinical studies developed a technology that allows an individual risk stratification, which saves many lives. Thus, this innovation is not only a highly interesting investment, but of high medical, clinical, sociological and economical relevance. Investors can participate actively in the company and profit from the future prospects. 8 www.demicco.ch

9. 2. Product/Service 9 www.demicco.ch

10. 2.Product 2.1Previous model BMDSys Optical GmbH with its team is the follow-up of BMDSys Production GmbH, which developed, produced and sold with the same staff the first systems for MFI diagnostics. With its research and development activities it achieved breaking results and international acknowledgement. For the first time a reliable system was available that could detect an enhanced risk for sudden cardiac death. Approx. 8 mio. EURO were invested in the industrialisation of the first version. 10 www.demicco.ch

11. 2.Product 2.1Previous model The systems of the first generation work perfectly and have successfully been used in various hospitals. However, the used technology requires liquid helium cooling, which means an expense of approx. 700 to 900 K EURO during a mean life cycle of 10 years. This generates high costs and reduces the economical effectiveness of the systems in the clinical use. This lack of economical efficiency of the previous model has reduced the chances in sales in such a way that the former company could not reach sustainable profit. 11 www.demicco.ch

12. 2.Product 2.2APOLLOCXS the new sensor generation Das team of BMDSys Optical GmbH developed, based on the original technology, a new system that makes the helium cooling superfluous. In this way the operating costs are importantly reduced. Thus, the new systems are highly interesting for any hospital worldwide that offers heart diagnostics. The prototype developed under the label APOLLO CXS is already available. All tests have been successful. Testfinished Prototypeready Moreefficient Directsales Distributors Lowmaintenancecosts Sportsorganisations ISOcertification Ordersareplaced! Readyformarket Cheaper Newtechnology Quickerproduction Withoutcooling 12 Useinhospitals Potentialhealthinsurances Highmargins(5060%) FirstmoverTechnology Internationaldemand Massproduction www.demicco.ch

13. 2.Product 2.3Projected development schedule To distribute the APOLLO CXS with the new optical technology (OPM) in clinics and medical centers, a series production has to be set up and financed. For the international market introduction a period of 1-2 years is scheduled. Already 8-12 months after project start, revenues are possible. The production time per system will be reduced in medium term to 4 weeks for being able to respond to the increasing demand. In 3 years an industrial mass production will become necessary. Developmentprocesses Phase1 Phase2 Phase3 Phase4 Phase5 Phase6 Developmentofthefirstsystem(helium) Testsinhospitalsanduniversities Firstmarketingnational DevelopmentAPOLLOCXS(OPM) TestAPOLLOCXS Internationalmarketing Startseriesproductionandmarketing Massproduction,worldwidesales Sales,marketing 13 Developmentphases today massproduction www.demicco.ch

14. 2.Product 2.3Projected development schedule Parallel to the development of the series production, direct and indirect sales channels will be set up to acquire new customers and advanced bookings. For systems based on the new technology, orders from the Chinese distributor are already included in the distribution contract with the previous company BMDSys Production GmbH. The marketing for the new technology has not been started yet. 14 www.demicco.ch

15. 2.Product 2.3Projecteddevelopmentschedule APOLLO CXS delivers information about the actual electrophysiological status of the heart based on the record of the hearts magnetic signals. The new system can become a standard diagnostic tool and can be easily combined with other diagnostics. APOLLO CXS provides in the handling of heart patients in the clinical routine a new parameter that surely in the future will be considered for inclusion in the guidelines of cardiology. APOLLO CXS leads to a paradigm change in cardiac diagnostics! 15 www.demicco.ch

16. 2.Product 2.3Projecteddevelopmentschedule ADVANTAGES: Quick and easy: An MFI examination takes maximum 5 minutes including data analysis. No patient preparation is necessary, not even undressing. Non-invasive: The sensor system is positioned over the patients chest, it does not touch the patient! Side-effect-free: The data acquisition is pure passive, no contrast agents are necessary and no ionizing radiation is used. Cost efficient: No helium cooling, room temperature leads to minimum operational costs. Repeatable: The examination can be repeated as often as required as there are no side effects. The diagnosis is applicable for all patient groups. 16 www.demicco.ch

17. 2.Product 2.4Production/productioncosts,salesprices Current production costs persystem based onthe new technology: 350,000EURO Production costs considering arationalized series production (from 2015) 280,000EURO Salesprices: Pricepersystem for direct sales 900,000EURO Pricepersystem for sales viadistributors: 500,000EURO 17 www.demicco.ch

18. 3. Managementteam 18 www.demicco.ch

19. 3.Managementteam 3.1VolkerSchall,CEO Volker Schall is a skilled banker and was able to successfully apply his knowledge in several production and sales companies in the sports industry. Because of his expertise in the sports industry he knows the demands and problems in this field and thus can take advantage of the enormous potential of this market. With his great experience as sales manager he is ideal for the scopes of marketing and sales of the optical diagnosis systems. Volker offers the whole necessary commercial and sales-related know-how for being able to lead BMDSys Optical GmbH towards a successful future. 19 www.demicco.ch

20. 3.Managementteam 3.2Dr.rer.nat.GertrudLembke,CTO Since finishing her studies in physics and her doctorate in 2007, Dr. rer. nat. Gertrud Lembke (Ms.) was involved in the development of the optical magnetometers as a scientific employee at the University Hospital Jena. Here, she extended her experience in the construction of a multichannel optical magnetic field sensor system as well as in simulation and construction of complex coil systems for well defined magnetic fields. For her work on this system she received in 2010 the price Young Investigator Award in the field instrumentation at the international conference for biomagnetism BIOMAG 2010. She has the necessary physical know-how for optimizing the system for the use in clinical routine. Gertrud is the technical developer from the start of the company. 20 www.demicco.ch

21. 3.Managementteam 3.3Furtherexecutivepersonnelandemployees Heike Kroker-Hge Dr. rer. nat. Reinhard Krsten Heike Kroker-Hge (Ms.) was responsible for the quality management of the superconducting MFI systems for a long time and knows the necessary steps for the registration of a medical product. Reinhard Krsten studied physics in Hamburg and obtained his doctorate in 2002. Furthermore, she has great experience as an executive assistant, in the scope of administration, national and international sales, export, import and purchase. Subsequently, he was employed at the Physikalisch-Technischen Bundesanstalt in Berlin in the field of biomagnetic diagnostic. He was responsible for the final assembly and testing of the present MFI systems as well as for their installation. His extensive knowledge regarding the behavior and treatment of highly permeable metal plates is of great importance for the future development. 21 www.demicco.ch

22. 3.Managementteam 3.3Furtherexecutivepersonnelandemployees MsC. Yingbin Wu Dipl.-Ing. Klaus Brandt Yingbin Wu works on the programming of the data acquisition and analysis software of the present MFI systems. As experienced development engineer in the field of medical engineering Mr. Brandt was involved in the whole production process of the helium cooled MFI systems since 2010. His knowledge and experience are of great importance for the adaption of the present programming to the optical magnetometers. Furthermore, Yingbin Wu is responsible for the contact to a Chinese distributor who currently sells the helium cooled systems in China. 22 In addition, as development and construction engineer, Klaus Brandt is responsible for the mechanical parts necessary for the operation of the system. www.demicco.ch

23. 3.Managementteam 3.3Furtherexecutivepersonnelandemployees Dr.-Ing. Dania Di Pietro Paolo Annett Veit Dania Di Pietro Paolo (Ms.) actively works in the field of biomagnetism since 12 years. She participates in the software development of the helium cooled MFI systems since 2005. Her focus was on the analysis and presentation of biomagnetic data. In cooperation with physicians she issued publications for conferences and professional journals. As software engineer, Annett Veit (Ms.) is responsible for the development and maintenance of the data bank. This contains the development of the patient administration system including the recording of medical data, the administration and analysis of anonymized study information, the development of the project-related data bank structure, the installation, administration and script development as well as the planning and configuration of replication solutions. Because of her advanced training in the scope of clinical studies she is an optimum employee for the establishment of the MFI diagnostic method in the clinical routine. 23 In addition to this, she participates in the preinstallation and training at the customers sites. www.demicco.ch

24. 4. Market 24 www.demicco.ch

25. 4.Marketoverview Specialhospitals, universities hospitals Cardiologists Prevention Medical prevention Prevention Sportscenters Modern practices The alternative diagnostic methods do not provide the precision, comfort, efficiency or a combination of the mentioned criteria. Some of the alternatives are invasive and/or put high side effects to the patient . Sportscenters Sports organisations Directsales 25 Largemedical centers Cardiological Sports The largest sales potential is in hospitals and large medical centers that offer heart diagnostics on the latest state of technology. APOLLO CXS offers acquisition, display and analysis of the magnetic signals of the human heart. Thus, several large diagnostic sectors in cardiology can be covered at the same time, e.g. risk stratification of future lifethreatening arrhythmias and detection of acute and stress induced ischemia. Medical facilities 4.1Targetgroups Salesviadistributors Admissionofhealth insurances www.demicco.ch

26. 4.Marketoverview 4.2Competitors AtB, Pescara (Italy) (A) Elekta, Stockholm (Sweden) (C) AtB was founded in 1990 and had cooperations with the universities of Ulm and Jena for some years. It carried out orders of the universities and delivered a system named Argos 200 for magnetic heart measurement to the university of Jena. This company is not significantly active any more since 2006 and never established an industrial production of MFI systems. AtB does not offer an optical technology! In a subsidiary of Elekta a system for electroencephalography (helmet shaped) is produced and sold. It is not possible to measure heart signals with this system and thus this product is no competition to our system. No optical technology available. CardioMag Imaging (USA) (B) In August 2010 the magnetocardiography (MCG) technology of KRISS was transferred to Biomagnetik Park GmbH. In January 2012 an MCG system of the company Biomagnetik Park GmbH was certified as a new medical device for the diagnose of coronary heart diseases according to the European Medical Directive 93/42/EEC. There is no compatible software for a risk stratification of sudden cardiac death. No optical technology available. Cardiomag sold in the past a 9-channel system for the measurement of the hearts magnetic field with which acute ischemia in the human heart can be detected. However, the recording bandwidth was so small and the noise so high that the system could not be used for risk stratification based on the QRS fragmentation. No optical technology available. 26 BMP Hamburg (Germany) (D) www.demicco.ch

27. 4.Marketoverview 4.2Competitors Thus, those suppliers are no real competition for the optical system of BMDSys Optical GmbH. The operation without helium is a unique selling proposition that is not offered by any competitor and saves approx. 900 K EURO of operation costs during 10 years (life cycle of a SQUID based MFI system). Thus, the optical MFI system APOLLO CXS is unique in the whole world. Competitor A Competitor B Competitor C Competitor D APOLLOCXS Price Performance Regionalmarket share Nationalmarket share Regional acceptance National acceptance Product range Marketing Innovation Companysize Onthe market since All systems of competitors are based on superconductive sensors, i.e. they require helium cooling for operation. 1990 2005 2000 2005 2010 2008 Legend: very high;high;moderate;low;very low 27 www.demicco.ch

28. 4.Marketoverview 4.3Marketpotential Themarketpotentialisenormous! Consideringthefactthatno comparableproductforheart diagnosticsisavailableuntilnow, BMDSys OpticalGmbHhasthe potentialforbeingaglobal playerinthissegment. ItcanbesupposedthatBMDSys OpticalGmbHfirstwillhavea monopolypositionontheglobal marketwithitsproduct. Thedevelopmentaledgeof approx.5yearscanhardlybe caughtupwithevenbylarger companiesthatwanttosetupa competition. 28 Marketcapacity global 600.0 bn Marketpotential 60.0 bn Marketvolume 240 mio. Scheduled market share until 2018 75% www.demicco.ch

29. 5. Chances and risks 29 www.demicco.ch

30. 5.Chancesandrisks Optimuminitialsituationforinvestors BMDSys OpticalGmbHisinaclassicnext level position.Themanagementanddevelopmentteam iswellattuned,themainproductisreadyformarket. Thenewlyfoundedcompanyiscompletelyfreefrom encumbrancesandcannowstartwithan appropriatefunding. Contrarytocomparabletechnologycompanies wherethemainpartoffinancialresourceshadtobe investedinresearchanddevelopmentBMDSys OpticalGmbHprovidesanearlyfinishedand marketreadyproduct. Chances Bestproduct onthe market Competitive edge can be secured incase of preferably soonest market entry Potentialfor globalplayer and market leader Worldwidehigh demand Existingorders Risks Handlingof the expectedgrowth 30 Supply bottleneck at suppliers of applicable material Copying of the technology by competitors (very difficult) www.demicco.ch

31. 6. Financialplanning 31 www.demicco.ch

32. 6.Financialplanning 6.1Salesfigures Salesplanning 2014 2015 2016 Price/system China(Transferof distribution contract) 500,000.00 0 7 12 Channeldirect sales 900,000.00 0 3 12 Channelhealth insurances 600,000.00 0 1 12 Channeldistribution 600,000.00 0 1 12 0.00 7,595,000.00 30,355,000.00 10,000.00 100,000.00 120,000.00 0.00 6,000.00 60,000.00 72,000.00 72,000.00 3,160,000.00 7,787,000.00 30,427,000.00 Revenues from sales Projectsponsorship by BMBF MaintenanceHamburg,BadOeynhausen Capitalinflow from investors Revenues intotal 3,000,000.00 Thesales figures of BMDSys OpticalGmbHespecially depend onthe production capacities to be managed.Incase of conservative planning,from 2015on12units,i.e.one system permonth,will be produced.This means aturnover of already 7.5mio.EURO.Up from 2016the production willbe increased to at least48units which means anaverage turnover of 30mio.EURO. 32 www.demicco.ch

33. 6.Financialplanning 6.2Costofmaterials Cost of materials IRFS(radiofrequency shielding) Coil material new sensor system holder new sensor system nonmagnetic, heightadjustable patient support Incidentals Cost of materials Cost of materialintotal 2014 1,000.00 350,000.00 2015 2016 140,000.00 25,000.00 15,000.00 10,000.00 10,000.00 10,000.00 150,000.00 360,000.00 0.00 0.00 0.00 0.00 0.00 12,000.00 4,200,000.00 4,212,000.00 0.00 0.00 0.00 0.00 0.00 48,000.00 13,440,000.00 13,488,000.00 Thecostsofmaterialarecalculatedproportionallytothesoldunits.Basedonthelongdeliverytime ofupto3monthsforsinglecomponents,purchasingandfinancinghastobescheduledaccordingly. 33 www.demicco.ch

34. 6.Financialplanning 6.3Costofpersonnel Cost of personnel 2014 Number of employees CEO CTO Dr.rer. nat. emp2 QAM emp3 Dr.rer.nat. emp4 Ms.C emp5 Dr.Ing. Projectadministration Dr.habil. emp6mdt Dipl.Ing. emp7mdt Ing. emp8 production assistant Sales2 Cost of personnel intotal: Sales2Bonus 8,500.00 8,500.00 6,000.00 6,000.00 6,000.00 6,000.00 4,000.00 6,000.00 6,000.00 4,500.00 3,000.00 2015 2016 7 90,000.00 90,000.00 60,000.00 60,000.00 60,000.00 60,000.00 40,000.00 60,000.00 60,000.00 0.00 0.00 9 108,000.00 108,000.00 72,000.00 72,000.00 72,000.00 72,000.00 48,000.00 72,000.00 72,000.00 49,500.00 108,000.00 19 168,000.00 168,000.00 144,000.00 144,000.00 144,000.00 144,000.00 144,000.00 108,000.00 108,000.00 108,000.00 144,000.00 565,000.00 888,000.00 1,366,800.00 0.00 135,000.00 540,000.00 Thecostsforpersonnelincreasewithincreasingproduction.Forthetwofounders(CEOandCTO)an additionalperformancerelatedbonussystemshouldbedeveloped. 34 www.demicco.ch

35. 6.Financialplanning 6.4Operationalcosts(withoutpersonnel) Operationalcosts Rent +heating Electrical current /person Telephone costs/person Internet Companycar Consultant CE+QMcosts Cleaning Marketing/PR Diverse Insurances Office supplies Travel expenses Clinicalstudies Hamburg Clinical studies BadOeynhausen other production costs Preparation and control of installation MaintenanceLaser Operationalcosts without personnel intotal 2014 5,600.0 200.00 50.00 50.00 900.00 4,000.00 1,200.00 250.00 500.0 1,300.0 500.00 0.00 6,000.00 6,000.00 10,000.00 8,000.00 700.00 2015 2016 61,100.00 15,400.00 3,850.00 550.00 9,900.00 40,000.00 13,200.00 2,750.00 18,000.00 4,250.00 14,300.00 5,500.00 20,000.00 60,000.00 60,000.00 0.00 0.00 7,700.00 67,200.00 21,600.00 5,400.00 600.00 19,200.00 48,000.00 14,400.00 3,000.00 57,000.00 6,000.00 15,600.00 6,000.00 68,000.00 72,000.00 72,000.00 110,000.00 32,000.00 8,400.00 67,200.00 45,600.00 11,400.00 600.00 30,000.00 48,000.00 14,400.00 3,000.00 120,000.00 6,000.00 15,600.00 6,000.00 96,000.00 72,000.00 72,000.00 720,000.00 280,000.00 8,400.00 336,500.00 626,400.00 1,616,200.00 Theoperationalcostscorrespondtothecommonscalesofatechnologicalcompanyofthis dimension.Theassignedstudycostsfallinthecategoryresearchanddevelopment. 35 www.demicco.ch

36. 6.Financialplanning 6.5Investments Investments 2014 Electronicshardware Production of Cscells SubventionUniversityof Ulm Softwarelicences Assetdeal 0.00 0.00 10,000.00 2,500.00 50,000.00 Investmentintotal: 2015 2016 140,000.00 80,000.00 10,000.00 2,500.00 50,000.00 282,500.00 0.00 0.00 10,000.00 2,500.00 0.00 12,500.00 0.00 0.00 0.00 2,500.00 0.00 2,500.00 Forthefirstoperationalyearonly280KEUROarenecessary,withwhichthewholetechnologyand themostimportantassetsofthepreviouscompanycanbebought.Thepreviouscompanyinvested duringitsoperationaltimeapprox.8mio.EURO.BMDSys OpticalGmbHcanproceedwithits acitvities completelyunencumbered. 36 www.demicco.ch

37. 6.Financialplanning 6.6CashFlowOverview CashFlow 2014 2015 2016 160,000.00 310,000.00 570,000.00 336,500.00 7,787,000.00 4,212,000.00 888,000.00 626,400.00 30,427,000.00 10,332,000.00 1,366,800.00 1,616,200.00 EBITDA: 1,051,500.00 1,925,600.00 19,728,000.00 CashFlowaccumulated: Cashflow: 1,948,500.00 1,666,000.00 3,874,100.00 3,579,100.00 23,302,100.00 23,007,100.00 Revenues Costs of materials Costs of personnel Operationalcosts without personnel Whencalculatingconservatively,untiltheendoftheyearonlyaturnoverof160Kisachievedthat resultsfrommaintenancecontracts.Butdependingonthetimeofthefinancinganddeliveringof components,within69monthssalesprofitscanbeachieved.Thecashflowofthefirstyear consideres alreadythepaymentofaninvestmentsumof3mio.EURO. Fromthesecondyearon(seebusinessplan)thecashflowofthecompanyispositive. 37 www.demicco.ch

38. 6.Financialplanning 6.7Capitaldemand Theactual capital demand of the company is 3mio.EURO. The capital will be used in the following ways: - Finishing the series-production readyness of the prototype APOLLO CXS - Optimizing the production - Set up of national and international sales - National marketing aktivities - Continuing the health insurance license - Prefinancing the existing and future orders 38 www.demicco.ch

39. 7. Offer for investors 39 www.demicco.ch

40. 7.Offerforinvestors 7.1Participation Interested investors can participate directly in the BMDSys Optical GmbH. Considering the sales and profit and the enormous market- and development potential the company today is rated with minimum 21 mio. EURO. The momentary proprietors offer investors a company share of up to 21 % for an exceptional price of 3 mio. EURO, which covers the momentary capital need. The mininmal investment is 500 K EURO per investor. 40 www.demicco.ch

41. 7.Offerforinvestors 7.2Exitstrategies The management teams searches investors for medium and long term attendance. The actual business plan was set up for 3 years. From the 4th year on an industrial production should be established, that covers the demand. It can be assumed that the company than faces another developmental step. Possible exit strategies from the momentary point of view: - Rebuy of shares through the company owner - IPO, Reverse Merger - M&A transaction 41 www.demicco.ch

42. Furtherquestions? Please contact us: De Micco & Friends Group Dr.LuigiCarloDeMicco eMail: Phone: Mobile: Web: luigi@demicco.ch +34871944532 +34637216267 www.demicco.ch VolkerSchall eMail: Phone: volkerschall@live.de +491778784978 Dr.rer.nat.GertrudLembke 42 eMail: Phone: G.Lembke@web.de +4917641428315 www.demicco.ch